Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled trial of Bimin Capsule for perennial allergic rhinitis
CTR20243364Phase 3Completed
- Sponsor
- Jinan Kangzhong Pharmaceutical Technology Development
- Start
- Oct 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in perennial rhinitis comparing Bimin Capsule with Matching placebo (2 arms). Primary endpoint: Change from baseline in mean total nasal symptom score during treatment. Started Oct 2024; status: completed.
02
Drugs
bimin
03
Conditions
perennial rhinitis
Beyond the preview
Go deeper on CTR20243364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243364.